12 results for "Colon and Rectal"

Colon and Rectal Surgery and the effects of E-101

This study is testing a new medicine to see if it helps prevent infections in the incision after colon or rectal surgery.

Rectal Cancer and the effects of Pinpoint, Fluorescence

This study is testing new imaging technology that is used during surgery.

Short Bowel Syndrome - A Multi-center Registry

This study is just observing patients who have short bowel syndrome for 10 years to learn more about this condition. There is no change in treatment if you participate in this study.

Colon Cancer and the Microenvironment of Stem Cells

This study is collecting specimens from patients who have cancer and from patients who do not have cancer to use in our cancer research lab.

Adenomas and Second Primary Colorectal Cancers and the effects of Eflornithine and Sulindac

The investigators hypothesize that the combination of Eflornithine and Sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Click here to download the Fast Facts

Colon Cancer and the effects of Standard Chemotherapy +/- Atezolizumab as Adjuvant Therapy

This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better than combination chemotherapy alone in treating patients with colon cancer.

Click here to download the Fast Facts

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR Metastatic Colorectal Cancer

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Click here to download the Fast Facts

Encorafenib + Cetuximab + Binimetinib vs. Irinotecan/Cetuximab or FOLFIRI/Cetuximab for mCRC

This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.

Click here to download the Fast Facts

Financial Burden Assessment in Patients with Stage I-III Colon or Rectal Cancer Undergoing Treatment

This research trial studies the financial burden in patients with Stage I-III Colon or Rectal Cancer who are undergoing treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient’s employment and finances.

Click here to download the Fast Facts

Trastuzumab + Pertuzumab or Cetuximab + Irinotecan for HER2/Neu Amplified Colorectal Cancer

This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and irinotecan hydrochloride in treating patients with colorectal cancer.

Click here to download the Fast Facts

M14-064: ABT-165 + FOLFIRI vs Bevacizumab + FOLFIRI for Metastatic Colorectal Cancer

A study to evaluate the efficacy and tolerability of ABT-165 + FOLFIRI compared to Bevacizumab + FOLFIRI in participants with previously treated metastatic adenocarcinoma of the colon or rectum.

Click here to download the Fast Facts

Rectal Cancer and the effects of Veliparib and Combination Chemotherapy

This randomized phase II trial studies how well veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib with combination chemotherapy and radiation therapy may kill more tumor cells and giving it before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Click here to download the Fast Facts